Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 2
Submit an article Journal homepage
126
Views
6
CrossRef citations to date
0
Altmetric
Correspondence

BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice

Ciprian TomuleasaDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania;Research Center for Functional Genomics and Translational Medicine, Cluj Napoca, RomaniaCorrespondence[email protected] [email protected]
,
Delia DimaDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
,
Ioana FrincDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
,
Mariana PatiuDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
,
Bobe PetrushevResearch Center for Functional Genomics and Translational Medicine, Cluj Napoca, Romania
,
Andrei CucuianuDepartment of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania;Department of Hematology, Iuliu Hatieganu University, Cluj Napoca, Romania
&
Ioana Berindan-NeagoeResearch Center for Functional Genomics and Translational Medicine, Cluj Napoca, Romania;Department of Genetics, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
 show all
Pages 546-547 | Received 23 Feb 2014, Accepted 23 Jun 2014, Published online: 19 Aug 2014
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
"BCR–ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice." Leukemia & Lymphoma, 56(2), pp. 546–547

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.